Making a difference for the patients – 4bases’ paper of the month “Enabling Technologies for Personalized and Precision Medicine”[1] Whereas last month we have read

We always hear about the highly celebrated Precision Medicine, but what is this in reality? An answer might be “the possibility to adopt a very

4bases proudly announces a new important step in its development plan. Thanks to an exclusive commercial partnership with the ILC Group, 4bases’ products and services

Manno, March 31, 2020 4bases SA, a swiss-based company specialized in the development, production and commercialization of reagent kits for NGS (New Generation Sequencing) is

Custom panel – developed on-demand for your specific RUO or CE-IVD specific applications.

To make your choice easier and faster 4bases’ company and product information are gathered in the new brochure

Manno, December 3st, 2019. 4bases SA, a Swiss-based company specialized in the development, production, and commercialization of reagent kits and gene assays for clinical NGS,

Since the end of May 2019, around 40% of patients with HR+/HER2- breast cancer can count on a new drug developed by Novartis and approved

After the renewal of our ISO13485:2016 certification in May, the entry of new products in our pipeline and the opening of new markets, the Swiss